LncRNA GAS8-AS1 is downregulated, correlates with early-stage disease and lymph node metastasis, and its knockdown promotes proliferation, migration, and invasion in differentiated thyroid cancer - Report - MDSpire
Advertisement
LncRNA GAS8-AS1 is downregulated, correlates with early-stage disease and lymph node metastasis, and its knockdown promotes proliferation, migration, and invasion in differentiated thyroid cancer
Clinical Report: Reduced Expression of LncRNA GAS8-AS1 in Thyroid Cancer
Overview
This study identifies that reduced expression of lncRNA GAS8-AS1 is significantly associated with early disease stages and lymph node metastasis in differentiated thyroid cancer (DTC). Silencing GAS8-AS1 enhances tumor cell proliferation, migration, and invasion, suggesting its role as a potential tumor suppressor.
Background
Thyroid cancer is the most common endocrine malignancy, with differentiated thyroid cancers (DTCs) accounting for the majority of cases. Understanding the molecular mechanisms underlying DTC progression is crucial for improving diagnostic and therapeutic strategies. LncRNAs, such as GAS8-AS1, have emerged as important regulators in cancer biology, yet their specific roles in DTC remain inadequately explored.
Data Highlights
Parameter
Value
GAS8-AS1 expression in DTCs vs normal tissues
p < 0.0001
Association with early-stage disease
p = 0.03
Association with lymph node metastasis
p = 0.03
Downregulation consistency across datasets
p = 0.004 (ENCORI)
Pan-cancer downregulation
p = 2.01 × 10-128 (TNMplot)
Key Findings
GAS8-AS1 expression is significantly downregulated in DTCs compared to normal tissues.
Lower GAS8-AS1 expression correlates with early-stage disease and lymph node metastasis.
24% of GAS8-AS1-associated genes are deregulated in DTCs.
Knockdown of GAS8-AS1 enhances proliferation, migration, and invasion of thyroid cancer cells.
Pathway analyses indicate GAS8-AS1 involvement in autophagy, apoptosis, and metastasis.
Clinical Implications
The findings suggest that GAS8-AS1 may serve as a valuable biomarker for early detection and prognosis in DTC. Clinicians may consider monitoring GAS8-AS1 levels to assess disease progression and metastasis risk in patients with thyroid cancer.
Conclusion
GAS8-AS1 appears to function as a tumor suppressor in differentiated thyroid cancer, with its downregulation linked to disease advancement. Further research is warranted to explore its potential as a diagnostic and prognostic tool.
